QHSLab (OTCQB:USAQ) Announces Launch of Q-Cog™ to Support Early Detection of Mild Cognitive Impairment and Dementia

Rhea-AI Summary

QHSLab (OTCQB:USAQ) on Dec. 3, 2025 launched Q-Cog™, a cloud-based digital cognitive assessment for primary care to identify Mild Cognitive Impairment and dementia risk earlier.

An initial real-world pilot of 168 patients aged 65+ identified 90 patients (54%) at high risk and enabled real-time telemedicine referrals. Q-Cog™ combines cognitive, behavioral, and functional screening in one workflow and is presented as aligning with CMS Annual Wellness Visit requirements, supporting documentation for neurocognitive and behavioral health CPT codes and Risk Adjustment Factor (RAF) scoring.

Positive

• 168-patient pilot with real-world data
• Identified 90 patients (54%) at high risk for cognitive impairment
• Supports CMS Annual Wellness Visit screening and neurocognitive CPT codes
• Enables real-time telemedicine referrals from primary care

Negative

• Pilot limited to 168 patients, scope is small
• No long-term clinical outcomes or validation results reported

News Market Reaction – USAQ

-17.39%

-17.39% Session close to close

In the Dec 3 session, USAQ declined 17.39%, reflecting a significant negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock dropped -17.4% in the session following this news. A negative reaction despite positive-so...

Analysis

The stock dropped -17.4% in the session following this news. A negative reaction despite positive-sounding product news fits a recent pattern where launches and service expansions were followed by declines of up to 17.39%. The Q-Cog™ tool expands reimbursable digital screening capabilities, but recent filings highlighted cash constraints, defaulted notes and going-concern language. Such background risk, combined with thin trading volume near $0.30 and well below the $0.4729 52-week high, could have amplified selling pressure after this announcement.

Key Figures

Pilot sample size: 168 patients High-risk patients: 90 individuals High-risk rate: 54% +5 more

8 metrics

Pilot sample size 168 patients Initial real-world Q-Cog™ pilot in patients aged 65 and older

High-risk patients 90 individuals Patients identified at high risk for cognitive impairment in pilot

High-risk rate 54% Share of 168 pilot patients flagged as high risk by Q-Cog™

Pilot age threshold 65 years Pilot included patients aged 65 and older

Unrecognized MCI cases More than 50% Proportion of Mild Cognitive Impairment cases missed in routine visits

Unrecognized dementia cases 60–80% Estimated share of dementia cases unrecognized during routine visits

Price change 24h -17.39% Share reaction after prior recording of this Q-Cog™ launch news

Price vs 52-week high -36.56% Distance from 52-week high before the current news

Historical Context

3 past events · Latest: Dec 03 (Positive)

Pattern 3 events

Date	Event	Sentiment	24h Move	Catalyst
Dec 03	Product launch	Positive	-17.4%	Launch of Q-Cog™ digital tool for early detection of cognitive impairment.
Sep 02	Product launch	Positive	-1.1%	Rollout of pediatric screening tool linking allergies and mental health.
Jul 08	Service expansion	Positive	-4.8%	Opening of Miami behavioral healthcare center using QHSLab digital platform.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent product and platform expansion news with generally positive tone has been followed by negative 24-hour price reactions, indicating a pattern of downside divergence on ostensibly favorable updates.

Recent Company History

Over the last few months, QHSLab has focused on expanding its digital health platform. On Jul 08, 2025 it opened a co-branded behavioral healthcare center in Miami, integrating AI-enhanced digital tools with in-person services, yet shares fell 4.76%. On Sep 02, 2025 it launched a pediatric screening tool, with a modest 1.05% decline. Today’s Dec 03, 2025 Q-Cog™ launch for early cognitive impairment detection also coincides with a 17.39% drop, reinforcing this divergence pattern.

Key Terms

mild cognitive impairment, dementia, telemedicine, cms screening guidelines, +4 more

8 terms

mild cognitive impairment medical

"designed to help primary care providers identify Mild Cognitive Impairment (MCI) and dementia-related"

Mild cognitive impairment (MCI) is a medical condition where a person experiences noticeable decline in memory or thinking that is greater than expected for their age but does not yet interfere significantly with daily life, like forgetting appointments more often while still managing basic tasks. For investors, MCI matters because it defines a target patient group, shapes the size and urgency of markets for diagnostics and treatments, and influences clinical trial design, regulatory pathways and potential revenue for companies developing related drugs or tests.

dementia medical

"identify Mild Cognitive Impairment (MCI) and dementia-related risks earlier in the disease process"

Dementia is a gradual decline in thinking, memory, and daily functioning caused by damage to the brain, like an operating system losing files and slowing down. Investors should care because dementia drives demand for healthcare services, long-term care, medicines, diagnostics, and caregiver support, creating large, long-term markets and cost pressures that affect healthcare companies, insurers, government spending, and workforce productivity.

telemedicine technical

"identified 90 individuals (54%) at high risk for cognitive impairment and facilitated real-time telemedicine referrals"

Telemedicine is the delivery of healthcare services remotely through digital communication tools, such as video calls or online messaging. It allows patients to consult with doctors and medical professionals without visiting a clinic in person. For investors, telemedicine represents a growing sector that combines technology and healthcare, potentially transforming how medical care is accessed and delivered worldwide.

cms screening guidelines regulatory

"empowering physicians to meet CMS screening guidelines while supporting risk adjustment"

CMS screening guidelines are the official recommendations and coverage rules issued by the U.S. Centers for Medicare & Medicaid Services that determine which medical screening tests are paid for, under what circumstances, and for which patient groups. For investors, these guidelines act like the rules of the road for healthcare products and services—changing them can expand or shrink the market, alter reimbursement rates, and shift demand for diagnostic tools, labs, and related treatments.

cpt codes regulatory

"qualifies for neurocognitive and behavioral health CPT codes"

CPT codes are standardized five-digit codes used to describe medical procedures, tests and services for billing, insurance reimbursement and data tracking. Think of them like barcodes for healthcare services: they tell payers what was done and influence how much providers get paid. Investors watch CPT codes because changes in coding, coverage or reimbursement rates can materially affect a healthcare provider’s revenue, equipment manufacturers’ sales and overall adoption of new treatments.

risk adjustment factor (raf) financial

"contributes to more accurate Risk Adjustment Factor (RAF) scoring for value-based providers"

A risk adjustment factor (RAF) is a numerical score that estimates how costly an insurance enrollee’s health care will be, based on their diagnoses and demographic profile. For investors, RAFs matter because they determine payments insurers receive and therefore affect revenue and profit margins—think of it like a risk grade that raises or lowers the insurer’s expected bill, similar to how a driver’s safety record changes auto insurance premiums.

value-based care financial

"digital platform expands company’s value-based care capabilities"

A health-care delivery approach that rewards providers for keeping patients healthy and improving outcomes instead of charging for each test or visit. For investors, it matters because it shifts where profits and losses come from—favoring providers and technologies that lower long-term costs, prevent complications, and demonstrate measurable results; think of it like paying a contractor only when the house stays sound, which changes who wins and loses financially.

social determinants medical

"behavioral health, daily function, and social determinants, we help clinicians understand"

Social determinants are the everyday non-medical factors — such as where people live, their income, education, job conditions, access to healthy food and safe housing — that shape health and life outcomes. They matter to investors because these factors influence consumer demand, healthcare costs, workforce productivity and long‑term risk for businesses and communities; thinking of them like the soil that helps a garden grow makes it easier to see how they affect financial returns over time.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Initial pilot of 168 patients aged 65 and older identifies 54% with high-risk cognitive scores; digital platform expands company’s value-based care capabilities. 

West Palm Beach, FL, Dec. 03, 2025 (GLOBE NEWSWIRE) -- QHSLab Inc. (the “Company”) (OTCQB: USAQ), a healthcare technology company focused on digital medicine and population health innovation, today announced the introduction of Q-Cog^™, a comprehensive, cloud-based cognitive assessment designed to help primary care providers identify Mild Cognitive Impairment (MCI) and dementia-related risks earlier in the disease process.

Q-Cog^™ combines validated cognitive, behavioral, and functional screening within a single digital workflow, empowering physicians to meet CMS screening guidelines while supporting risk adjustment and reimbursement under neurocognitive and behavioral health codes.

Juan Oms, MD, Psychiatrist and Medical Adviser
“Primary care clinicians are the first line of defense for cognitive decline,” said Dr. Juan Oms, Psychiatrist and Medical Adviser to QHSLab. “Q-Cog^™ equips them with a validated, patient-friendly digital tool to identify at-risk individuals and initiate early support before dementia becomes disabling.”

In an initial real-world pilot among 168 patients aged 65 and older, Q-Cog^™ identified 90 individuals (54%) at high risk for cognitive impairment and facilitated real-time telemedicine referrals—underscoring the significant unmet need for early detection in primary care. Despite national guidelines, more than 50% of Mild Cognitive Impairment cases and up to 60–80% of dementia cases go unrecognized during routine visits. This persistent diagnostic gap, driven by time pressures and limited tools, leaves many patients undetected until functional decline is apparent. Q-Cog^™ bridges this gap by delivering a fast, structured, digital assessment that enables primary-care clinicians to identify risk earlier and initiate timely, evidence-based follow-up.

Troy Grogan, President and CEO of QHSLab
“Early detection is where primary care can make the biggest impact,” said Troy Grogan, President and CEO of QHSLab. “Q-Cog^™ gives physicians a practical, reimbursable way to screen for cognitive decline during routine encounters, while also capturing data that supports value-based care and population-health performance.”

For investors, the launch of Q-Cog^™ represents a meaningful expansion of QHSLab’s reimbursable digital medicine platform. The solution aligns directly with CMS Annual Wellness Visit requirements, supports cognitive and behavioral health screening mandates, and generates documentation that qualifies for neurocognitive and behavioral health CPT codes. By identifying high-risk patients earlier, Q-Cog^™ also contributes to more accurate Risk Adjustment Factor (RAF) scoring for value-based providers—improving both care outcomes and financial performance. With few practical tools currently in widespread use at the primary-care level, Q-Cog^™ fills a critical gap in early dementia detection while opening new, scalable revenue opportunities for QHSLab and its provider partners.

Marcos Sánchez-González, MD, PhD, Vice President of Medical and Scientific Affairs
“Q-Cog^™ reflects our commitment to whole-person assessment,” said Dr. Marcos Sánchez-González, QHSLab’s Vice President of Medical and Scientific Affairs. “By integrating cognitive testing with behavioral health, daily function, and social determinants, we help clinicians understand not only the impairment but also the context — and that’s where prevention and effective care truly begin.”

About QHSLab
QHSLab, Inc. (OTCQB: USAQ) is a digital health technology leader providing preventive screening, assessment, and workflow solutions for primary care providers. Its tools help practices identify, document, and manage underdiagnosed chronic and behavioral conditions efficiently and profitably. Learn more at www.qhslab.com

Forward-Looking Statements 
Certain matters discussed in this press release are ‘forward-looking statements’ intended to qualify for the safe harbor from liability established by the Private Securities Litigation Reform Act of 1995. In particular, the Company’s statements regarding trends in the marketplace, future revenues, future products, and potential future results and acquisitions are examples of such forward-looking statements. Forward-looking statements are generally identified by words such as ‘may,’ ‘could,’ ‘believes,’ ‘estimates,’ ‘targets,’ ‘expects,’ or ‘intends,’ and other similar words that express risks and uncertainties. These statements are subject to numerous risks and uncertainties, including, but not limited to, the timing of the introduction of new products, the inherent discrepancy in actual results from estimates, projections, and forecasts made by management, regulatory delays, changes in government funding and budgets, and other factors, including general economic conditions, not within the Company’s control. The factors discussed herein and expressed from time to time in the Company’s filings with the Securities and Exchange Commission could cause actual results and developments to be materially different from those expressed in or implied by such statements. The forward-looking statements are made only as of the date of this press release. The Company undertakes no obligation to publicly update such forward-looking statements to reflect subsequent events or circumstances.

Investor Relations Contact:

Olivia Giamanco
QHSLab, Inc.
(929) 379-6503
ir@usaqcorp.com
https://twitter.com/QHSLabInc

FAQ

What did QHSLab (USAQ) announce on Dec. 3, 2025 about Q-Cog™?

QHSLab announced the launch of Q-Cog™, a cloud-based cognitive assessment for primary care to detect MCI and dementia risk earlier.

How many patients were in Q-Cog™'s initial pilot and what were the results for USAQ?

The initial real-world pilot included 168 patients aged 65+ and identified 90 patients (54%) at high risk for cognitive impairment.

Does Q-Cog™ support Medicare/CMS screening and billing for USAQ customers?

Yes; Q-Cog™ is described as aligning with CMS Annual Wellness Visit requirements and generating documentation that supports neurocognitive and behavioral health CPT codes.

How does Q-Cog™ affect primary-care workflows according to USAQ?

Q-Cog™ integrates cognitive, behavioral, and functional screening into a single digital workflow to help clinicians identify at-risk patients and initiate timely follow-up.

Did QHSLab report clinical outcomes or long-term validation for Q-Cog™ (USAQ)?

No long-term clinical outcomes or broader validation results were reported in the announcement; only initial pilot identification and telemedicine referrals were described.